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1. Introduction 
Duchenne Muscular Dystrophy (DMD) is a fatal, X chromosome-inherited disease which 
affects the whole world population equally and has an incidence of 1 in 3500 boys. The 
disease is progressive in nature with the first signs of muscle wasting appearing as early as 
age 3 (Dubowitz 1975; Jennekens et al. 1991). The disease slowly weakens the skeletal 
muscles of the arms and legs (mostly muscles of shoulder and pelvic girdles) and abdomen. 
By the early teens, heart and respiratory muscles may also become affected. Nearly all 
children with DMD lose the ability to walk between the age of 7 and the early teen years, 
with activities involving the arms, legs or trunk requiring assistance or mechanical support. 
Patients are typically confined to a wheelchair and they rarely survive the fourth decade of 
their life. Most DMD patients die due to respiratory or cardiac failure because of the 
progressive damage to the diaphragm or cardiac myopathy. A milder form of muscular 
dystrophy, termed Becker Muscular Dystrophy (BMD), has been characterized with a 
milder clinical presentation (Becker 1955). Children with this variation remain physically 
active and independent later in life compared to DMD patients. Symptoms begin to appear 
after 20 years of age and patients live longer compared to DMD patients. 
Histologically, muscles from DMD patients are characterized by increased variation in 
muscle fiber size, necrosis of individual muscle fibers and replacement of necrotic fibers by 
fibrofatty tissue (Emery 1995; Engel 1994). In addition, an increase in serum Creatine Kinase 
(CK), derived from degenerating muscle fibers, has been recognized as one of the main 
diagnostic characteristics of the disease (Engel 1994; Guyton 1995). In 1983, Kay Davies of 
London, England found linkage between a DNA marker and the DMD gene located on the 
short arm of the X chromosome (Xp21) (Davies et al. 1983). This discovery finally confirmed 
the long time theory that DMD inheritance is through the X chromosome and explained 
Duchenne’s notes of affected boys while girls remained without symptoms. 
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The culmination of DMD research occurred in 1986 when Louis Kunkel of Boston, United 
States of America (USA) isolated and cloned the gene which caused DMD / BMD (Kunkel et 
al. 1986). One year later (1987) Eric Hoffman from the same laboratory identified the protein 
product of the DMD / BMD gene (Hoffman et al. 1987). This protein was called dystrophin. 
The discovery of the dystrophin gene mutation as the cause of DMD opened the door for 
diagnostic development and therapeutic strategies for this disease (Bogdanovich et al. 2004). 
1.1 Dystrophin 
Disease symptoms are progressive and characterized by quantitative and qualitative 
changes in dystrophin protein (Brown 1997; Khurana et al. 1990). The dystrophin gene is 
located on the short arm of chromosome Xp21 and is a large gene comprised of 79 exons. 
With a total size of 3Mb, the gene represents about 0.1% of the entire human genome. The 
dystrophin protein consists of 3645 amino acids (AA) and has a molecular mass of 426 kDa 
(Coffey et al. 1992; Monaco et al. 1986). The molecule can be divided into 4 parts: an N-
terminal actin binding domain, a central rod, a cysteine rich segment and a C-terminal end 
(Einbond & Sudol 1996; Koenig et al. 1988; Ponting et al. 1996; Roberts et al. 1996;). 
Dystrophin forms a link between the extra and intra-cellular cytoskeleton, and it is 
hypothesized that dystrophin acts to neutralize stressful events that come from outside the 
cell toward the intracellular matrix, although the full function of dystrophin is still 
unknown. With a lack of dystrophin protein, the sarcolemma is susceptible to contraction-
induced ruptures and permanent cell damage is inevitable (Wrogemann & Pena 1976). 
Previous experiments have demonstrated an influx of extracellular Ca2+ or sarcoplasmatic 
reticulum leakage due to membrane disruption, which can result in proteolitic activities by 
Ca2+ dependent proteases. This cycle leads to necrosis, inflammatory cell infiltration, and 
phagocytosis. Additionally, the presence of mast cells can stimulate the release of basic 
fibroblast growth factor (bFGF) which contributes to fibrotic changes in dystrophic muscle. 
The clinical presentation of DMD depends on the nature of the dystrophin gene mutation 
mutation. Nonsense mutations in the DMD gene lead to a premature stop codon that blocks 
dystrophin translation (Hoffman et al. 1987). In the case of a frame shift mutation, there is an 
exchange of one nucleotide base with another, resulting in the synthesis of shorter or longer 
dystrophin variants. These mutations result in a milder clinical presentation, namely BMD, 
where expression of dystrophin protein is present but reduced (Monaco et al. 1988). 
Dystrophin mutations can be localized in any of its 4 parts and the mutation localization is 
in direct correlation with the severity of clinical disease presentation. The most severe cases 
of DMD are described with mutations in the cystein rich component because of its multiple 
functions (Beggs et al. 1991; Koenig et al. 1989), while mutations in the other 3 parts result in 
milder clinical presentation. 
Disease diagnosis starts with taking a careful history of the disease as well as laboratory 
testing. The level of CK in the blood is significantly higher in DMD patients, especially at the 
beginning of the disease, where it can often be 10 times higher compared to normal (Engel 
1994). Many advantages are achieved by genetic analysis of DMD mutations. It is possible to 
discover mutations in the DMD gene using polymerase chain reaction (Flanigan et al. 2003; 
White et al. 2002). These methods are used routinely in prenatal diagnosis of male fetuses. 
Typically, DMD patients become wheelchair bound before 13 years of age, while BMD 
patients can remain physically active after 16 years of age. More invasive methods such as 
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electrodiagnostics and muscle biopsy are used in cases of negative genetic analysis, for the 
differential diagnosis between DMD and BMD, and especially in autosomal disorders such 
as Limb-Girdle Muscular Dystrophy, where big differences between clinical presentations 
and laboratory testing do not exist (Laval & Bushby 2004). In such cases, muscle biopsy 
samples are used for histopathology and immunohistochemistry examination.  
2. Mouse models of DMD 
The identification and utilization of animal models in biomedical research is a necessary 
step in evaluating disease pathology and designing effective therapies for that disease (Table 
1). In 1984, a mouse model of DMD was identified and has been termed the mdx mouse (mdx 
= muscular disease x-chromosome). The identification of a mouse model for DMD proved to 
be useful for further understanding of both the normal function of dystrophin and the 
pathology of the disease (Petrof et al. 1993; Stedman et al. 1991), and the mdx mouse 
currently remains the most widely used mouse model of DMD (Brockdorff et al. 1987; 
Cavanna et al. 1988). Mdx mice have a natural mutation in the dystrophin gene, caused by a 
point mutation. Compared to human DMD patients, mdx mice have a relatively mild disease 
presentation, characterized by periods of muscle fiber degeneration and regeneration 
starting approximately 2 weeks after birth although not all muscles are similarly affected. 
Despite the milder disease phenotype in these mice, the characteristic cycles of muscle fiber 
degeneration and regeneration provide a variable to evaluate therapies in this mouse model. 
In addition, biochemical analyses have demonstrated that there is a consistent increase in 
serum CK in the mdx mouse, mirroring an important biomarker in human patients (Bulfield 
et al. 1984; Moens et al. 1993). Inasmuch as there are recognized limitations of this mouse 
model, the mdx mouse remains a widely used animal in biomedical research.  
The mdx mouse is very suitable for experiments designed to elucidate function and causality of 
the disease, as well as for gene and pharmaceutical therapy. It is in fact proving to be useful for 
furthering our understanding on both the normal function of dystrophin and the pathology of 
the disease. Experiments using mdx mice have provided us with invaluable information 
regarding the function of the gene product involved in DMD as well as the dystrophin-
associated proteins (DAP) and the dystroglycan/sarcoglycan complex (DGC/SGC). 
Additional allelic variants of the original mdx mouse mutation were created by treating mice 
with the mutagen, N-ethylnitrosourea (Rafael et al. 2000). This resulted in the formation of 4 
new mouse models with specific mutations in the dystrophin gene and relevant increases in 
circulating CK levels in the blood. These mouse models have been described previously 
(Chapman et al. 1989; Cox et al. 1993; Im et al. 1996). Briefly, the mdx2cv mouse has a mutation 
in intro 42; the mdx3cv mouse has a mutant splice acceptor site in nintron 65; the mdx4cv mouse 
has a "C" to "T" substitution in exon 53; and mdx5cv has an "A" to "T" transition in exon 10. Due 
to the different sites of these point mutations, different dystrophin isoforms can be expressed 
in the form of revertant fibers. It has been proposed that these strains of mdx mice may be 
usefule to elucidate the role of these various dystrophin isoforms, although the original mdx 
variant remains the mouse model most utilized (Banks & Chamberlain 2008). 
The mild phenotype of mdx mice is a recognized limitation of this mouse model. For 
example, mdx mice maintain cage activity and do not have significant exercise limitations 
(De Luca et al. 2003). Indeed, forced treadmill exercise has been used as a way to increase 
the degree of muscle pathology present in these mice (Fraysse et al. 2004). Also, there is only 
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approximately a 20% difference in the lifespan of the mdx mouse compared to wild-type, 
thus limiting the ability to detect a therapy-based improvement on lifespan (Chamberlain et 
al. 2007). For these reasons, a more severe mouse model was developed that introduced the 
knockout of the utrophin gene into the mdx mouse; thus creating the dystrophin:utrophin 
double knockout mouse (DKO) (Deconinck et al. 1997, 1998; Grady et al. 1997; Huang et al. 
2011). These mice have a severely limited lifespan coupled with severe impairments in 
muscle function (Chamberlain et al. 2007). 
 
Most commonly used mouse models in muscular dystrophies 
Muscular Dystrophy Gene product Mouse model 
Duchenne/Becker MD Dystrophin mdx, mdx2-5cv, mdx:utr-/- 
Limb-Girdle MD   
Type 1C Caveolin 3 cav3-/- 
Type 2A Calpain 3 capn3-/- 
Type 2B (Miyoshi myopathy) Dysferlin SJL, A/J 
Type 2C ┛-Sarcoglycan Sgcg-/- 
Type 2D ┙-Sarcoglycan (Adhalin) sgca-/- 
Type 2E ┚-Sarcoglycan sgcb-/- 
Type 2F ├-Sarcoglycan sgcd-/-  
Congenital MD (CMD)  dy, dy2J, dy3k, dyw, dyPAS 
Table 1. Mouse models in MDs 
3. Current progress and evaluation 
It has recently been proposed that a set of standard operating procedures be established for 
evaluating pre-clinical testing data in mdx mice (Grounds et al. 2008; Nagaraju & Willmann 
2009; Spurney et al. 2009; Willmann et al. 2011). Through the universal adoption of 
standardized laboratory assays, the results of multiple pre-clinical trials performed in 
independent laboratories could be evaulated. The laboratory assays that we have employed in 
designing our new scaling system have been identified as robust tests for evaluating endpoints 
in the mdx mouse (Spurney et al. 2009). Before introducing the new scaling methodology, we 
will review the results of a number of preclinical trials performed in the mdx mouse. The data 
from these trials will then be utilized in presenting and evaulating the new scaling system, we 
call the Multiparametric Muscle Improvement Score (MMIS). These preclinical trials use a 
variety of parameters to establish the beneficial effect of the administered compound, and can 
be catogorized as either functional, morphological, or biochemical. Functional evaluation was 
done using a specially designed system to quantify ex vivo isometric and eccentric contractions 
(ECC) in freshly dissected muscle. Morphologic measures were quantified from hematoxylin 
and eosin (H&E) or immuno-stained muscle sections, and included counting of total muscle 
fibers, single fiber cross-sectional area, and the percentage of centrally nucleated fibers. 
Determination of serum creatine kinase and up-regulation of utrophin constituted the 
biochemical evaluation. Improvement in any of these individual parameters would suggest a 
therapy-based improvement in the dystrophic phenotype in mdx mice. However, some 
parameters are suggestive of more significant clinical improvement (i.e. greater muscle force, 
lower serum CK) and are therefore given more weight in our scaling system. 
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Preclinical trials were performed to determine the extent that small molecule therapies could 
up-regulate utrophin, and therefore functionally compensate for the loss of dystrophin in the 
muscles of mdx mice. These small moleculaes included heregulin (Krag et al. 2004) and 
biglycan (Amenta et al. 2011). In general, these utrophin-based up-regulation strategies 
resulted in very similar benefits in the mdx mouse. Parameters that were improved included 
isometric force following ECC, increased regenerative capacities of mdx muscle (i.e. greater 
number of regenerative fibers), and less necrotic areas in the diaphragm muscle. However, 
these strategies did not show improvements isometric force producing capacity of limb 
muscles or the levels of serum creatine kinase. The improvements in the ECC force coupled 
with the up-regulation of utrophin demonstrate that utrophin can functionally substitute for 
the loss of dystrophin. However, the incomplete amelioration of the dystrophic phenotype 
suggests that these therapies have limitations when administered individually. 
A number of preclinical studies were performed to analyze the effects of blocking the 
activity of myostatin, a negative regulator of muscle growth and member of the TGF-β 
family (McPherron et al. 1997; McPherron & Lee 1997). Strategies included using antibodies 
directed against myostatin and administration of the myostatin propeptide, to sequester 
circulating myostatin and neutralize its activity. Administration of these compounds to mdx 
mice resulted in significant improvements in overall body and skeletal muscle mass. Muscle 
mass increases were greater in response to the myostatin propeptide, and may be due to a 
higher binding affinity for myostatin compared to the myostatin antibody (Bogdanovich et 
al. 2002, 2005). In addition, muscle function was improved as evidenced by greater absolute 
forces in muscles from treated mice in both trials. However, the propeptide-based strategy also 
resulted in improvements in specific force (i.e. force normalized to muscle cross-sectional 
area). Both strategies demonstrated improvements in overall muscle histopathology and the 
levels of serum creatine kinase, suggesting an improvement in the sarcolemma by a utrophin 
independent mechanism. Collectively, these myostatin blockade strategies were effective in 
stimulating increases in muscle mass and muscle function, along with measures of muscle 
histopathology and serum CK. However, complete amelioration of the dystrophic 
phenotype was not accomplished due to the fact that no improvements were noted in the 
force loss following eccentric lengthening contractions.  
Furthermore, we wanted to determine whether myostatin blockade would be beneficial to 
additional mouse models of muscular dystrophy. We utilized the myostatin-antibody 
strategy in gamma sarcoglycan (Sgcg-/-) knockout mice, a model of Limb-Girdle 2C muscular 
dystrophy (LGMD 2C) (Bogdanovich et al. 2008). Interestingly, myostatin antibody blockade 
did not show desired improvement in this mouse model. Improvement was minimal and 
evident in body and muscle weight increases. Physiological improvement was notable only 
in one parameter, absolute force improvement. Histopathological and biochemical 
parameters were unchaged when compared to control mice. Therefore, unique disease 
charactersitics of LGMD 2C compared to DMD in mouse models may have led to these 
differing results and a preferential benefit in the mdx mouse.  
Recently, we tested the efficacy of a novel myostatin blockade strategy using a soluble form 
of the activin type IIB receptor (ActRIIB) (Pistilli et al. 2011). The ActRIIB is the receptor for 
myostain as well as other member of the TGF-β superfamily. The solubilized form of the 
receptor (sActRIIB) would be able to bind to and sequester multiple TGF-β superfamily 
members, thereby potentially providing a greater therapeutic effect. In this preclinical trial, 
two doses of sActRIIB were utilized, a low dose of 1,0 mg/kg bodyweight and a high dose 
10,0 mg/kg bodyweight. Notable differences were observed when comparing these two 
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dosing strategies. The high dose of sActRIIB resulted in dramatic increases in body weight 
and lean muscle mass, while minimal changes in overall body mass were noted in the 
response to the low dose. Both doses of sActRIIB improved absolute forces produced by limb 
muscles. However, the low dose significantly improved specific force, indicating an 
improvement in force producing capacity independent of muscle size. Serum CK levels were 
also lower in sActRIB treated mice. Unfortunately, force loss follwing eccentric lengthening 
contractions and muscle histopathology were not significantly improved in these trials. 
Therefore, as with the myostatin antibody and the myostatin propeptide, complete 
amelioration of the dystrophic phenotype was not observed with sActRIIB therapy.  
The results of these trials demonstrate that small molecule-based therapies have the 
potential to improve a number of paremeters related to the dystrophic phenotype in mdx 
mice. However, as noted, no therapy has been able to completely ameliorate the phenotype 
and rescue the mdx mouse. Also, evaluating the therapeutic efficacy of drugs identified 
through preclinical trials is inefficient, due to the large number of preclinical trials published  
 
Table 2. Multiparametric Muscle Improvement Score 
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in animal models, and the differential methodology used to evaluate the data. Therefore, a 
scaling system that can evaluate the therapeutic efficacy of independent preclinical trials 
would be useful to identify those compounds with the most therapeutic promise. The purpose 
of this research was to formulate a single, objective scoring system to evaluate preclinical trial 
data arising from multiple laboratories. More detailed and precise quantification of different 
therapies can be obtained by utilizing the Multiparametric Muscle Improvement Score (MMIS) 
system (Bogdanovich 2009). 
4. Methods 
The authors have complied preclinical trial data acquired during the last 10 years, and 
evaluated the data using the MMIS scoring system (Bogdanovich 2009). This system consists 
of ten of the most important anatomical, physiological and biochemical elements directly 
related to improvement of the dystrophic phenotype in mouse models of muscular 
dystrophy. These include: body and muscle weight changes, muscle force production 
during isometric and lengthening contractions, evidence of histological improvement, and 
reductions in circulating creatine kinase (see Table 2). These elements are weighted with one 
single numerical value from 1 (least important) to 5 (most important). Only statistically 
significant improvements in measured parameters can be scored. Scoring is done in such a 
way that every parameter receives maximal value if there is improvement. Scored elements 
are summarized at the end and the final number is the improvement score. 
 
Table 3. Evaluation of possible therapeutic stratagies for muscular dystrophy (before MMIS 
system) 
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5. Results 
The scoring system is objective and excludes human error. It is possible to review and rank 
therapies based on a final single numeric score using the MMIS scale. With the MMIS scale, 
we have objectively assessed the therapeutic efficacy of multiple drug therapies in mouse 
models of muscular dystrophy (mdx mouse, Sgcg-/- mouse) (Table 3, 4). However, the 
limitations of these promising methods were identified objectively using the MMIS scale. 
Despite significant effects on muscle mass and muscle force production, neither strategy 
completely ameliorated the dystrophic phenotype with regards to eccentric lenghtening 
contractions or histological improvement as identified using the MMIS scale. 
 
Table 4. Possible therapeutic stratagies for muscular dystrophy (MMIS system) 
6. Conclusion  
Currently, there is a need for standardization of measurement and objective evaluation of 
different preclinical studies of the muscular dystrophies, which would allow for a better 
understanding of the disease and its response to potential therapies. We suggest that the 
MMIS provides a single numeric value useful for cross-comparing different preclinical 
studies and prioritizing drug development for muscular dystrophy therapy. We suggest 
that the use of the MMIS scale will allow for precise and rigorous evaluation of functional 
improvements of therapeutic interventions performed in preclinical trials. 
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